

RESEARCH

Open Access



miR-221-3p, arterial blood gas, and lung ultrasound: a multimodal approach for predicting neonatal respiratory distress syndrome outcomes

Meixin Liang^{1†}, Tao Pan^{2†}, Yanan Hou³, Zhihua Liu³, Zhiqiang Liu³, Jing Mo⁴, Yang Zhang^{3*} and Jinfeng Wen^{5*}

Abstract

Background Neonatal respiratory distress syndrome (NRDS) is one of the critical illnesses causing early death in infants due to alveolar surface-active substance deficiency, and the prognosis may show varying degrees of sequelae. Some miRNAs are valuable in the prognosis of NRDS infants. The objective of this research was to assess the predictive value of combining the three factors on the prognosis of NRDS infants by analyzing miR-221-3p levels, arterial blood gas analysis parameters and lung ultrasound (LUS) scores in NRDS infants with good and poor prognosis.

Methods Serum miR-221-3p levels were measured by qRT-PCR. Effect of miR-221-3p expression in prognosis of NRDS infants using Kaplan-Meier curve and COX analyses. Arterial blood gas parameters were analyzed, as well as LUS score was recorded for NRDS infants. Role of miR-221-3p combined with arterial blood gas parameters and LUS score in prognosis of NRDS infants was assessed by ROC curves. Pearson correlation was applied to assess the association of miR-221-3p with arterial blood gas analysis parameters and LUS score.

Results Serum miR-221-3p was notably greater in NRDS infants than in healthy newborns. High miR-221-3p level was related to poor prognosis for NRDS infants. pH and PaO₂ were lower and PaCO₂ was higher in arterial blood gas analysis parameters in poor prognosis. Furthermore, LUS score was greater on poor prognosis as opposed to good prognosis. miR-221-3p combined with arterial blood gas parameters and LUS score has a high accuracy in predicting prognosis in NRDS infants. Moreover, miR-221-3p was associated negatively with pH and PaO₂ and positively with PaCO₂ and LUS score.

Conclusions Elevated miR-221-3p may be related to poor survival outcomes in NRDS infants. miR-221-3p in combination with arterial blood gas parameters and LUS score has a high accuracy in determining the survival outcome of NRDS infants and may be a useful tool for clinical NRDS prognosis.

[†]Meixin Liang and Tao Pan are joint first author.

*Correspondence:

Yang Zhang
Zhangyangslchos@163.com
Jinfeng Wen
Wenjinfenghg@163.com

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Keywords miR-221-3p, NRDS, Arterial blood gas analysis, LUS score, Prognosis

Background

Neonatal respiratory distress syndrome (NRDS), otherwise called neonatal pulmonary hyaline membrane disease, is a disease attributed to alveolar atrophy due to structural immaturity of the lungs and insufficient production of lung surface-active substances [1]. The primary clinical symptoms are dyspnea, shortness of breath, cyanosis, nasal instigation, and even respiratory failure in severe cases, endangering the lives of infants [2]. Especially in preterm infants, the occurrence of NRDS is higher and the disease progresses more rapidly, which is one of the major factors of death in preterm infants, as well as an acute and critical condition in neonatology [3]. Therefore, early detection and therapy of NRDS is critical to neonatal lives.

The determination of diagnosis and post-treatment observation of NRDS in current clinical work is based on clinical manifestations, blood gas analysis, X-ray and lung ultrasound (LUS) score [4, 5]. Infants are primarily managed clinically with pulmonary surface-active substances and ventilation support, but the prognosis of some infants with standardized treatment is still poor and death occurs [6, 7]. Hence, we considered searching for effective prognostic factors for NRDS infants at the molecular level, to enhance resuscitation success rate and to improve prognosis.

Abnormal expression of microRNAs (miRNAs) under different pathological conditions is an essential indicator of disease progression and prognosis [8]. The function of MiRNAs in the diagnosis and prognosis concerning respiratory distress continues to be discovered [9]. Previous work identified abnormal miR-221-3p expression for lung disease, with upregulated expression in acute pulmonary embolism combined with pulmonary hypertension, non-small cell lung cancer, and lung adenocarcinoma [10–12]. Notably, miR-221-3p was identified in blood exosomes from patients with acute respiratory distress syndrome that exhibited an upregulation trend [13]. Nonetheless, the value of miR-221-3p on NRDS remains unexplored.

Accordingly, the research question we posed was what role does miR-221-3p combined with arterial blood gas analysis and LUS score play in NRDS? The aim of the research was to evaluate prognostic value of combining the three elements on NRDS infants by analyzing the relationship of miR-221-3p expression level with arterial blood gas parameters and LUS score in infants with good and poor prognosis. We analyzed the variability and correlation of miR-221-3p levels, arterial blood gas parameter levels and LUS score in NRDS infants with different prognostic outcomes. Moreover, the prognostic value of

miR-221-3p combined with arterial blood gas parameters and LUS score for NRDS infants was investigated. In order to contribute to the prognostic assessment of NRDS infants in the clinic.

Methods

General information collection of research objects

The study was endorsed by the Ethics Committee of Shengli Oilfield Central Hospital and guardians of neonates voluntarily signed an informed consent.

Sample size calculations based on G-power 3.1.9.7, the necessary sample size of each group was estimated to be more than 88 in the case of an alpha error probability of 0.05 and p power (1-beta) of 0.95. Therefore, a total of 122 infants with NRDS hospitalized in Shengli Oilfield Central Hospital from 2018 to 2023 and 99 healthy infants born during the same period were admitted to this research using a case-control study method. The diagnosis of NRDS is essentially in accordance with clinical symptoms and imaging phenomena, which are manifested by a respiratory rate of > 60 breaths/min, dyspnea, tachypnoea, cyanosis, intercostal or subcostal or suprasternal retraction, bronchial congestion, and frothy mouth. Additionally, chest X-ray findings revealed typical manifestations such as decreased transparency of both lungs, blurring of the cardiac and diaphragmatic margins, ground-glass changes, bronchial gas signs, and white lungs. The inclusion criteria for NRDS infants were that all parameters were premature infants with a gestational age of 28–37 weeks, the children met the diagnostic criteria for NRDS, and the clinical history was complete. Exclusion criteria were primary alveolar surface-active substance deficiency, diseases such as congenital heart failure, dyspnea with infectious pneumonia or diaphragmatic hernia. Inclusion criteria for the healthy group were neonates with a gestational age of 28–37 weeks, no other postnatal infections, and exclusion of confounding factors such as congenital developmental anomalies, inherited metabolic and chromosomal disorders.

General information about the subjects of the study was gathered, including gender, gestational age, birth weight, height and delivery mode.

Arterial blood gas analysis

After delivery of the neonate and cutting of the umbilical cord, 2 mL of umbilical artery blood was withdrawn by syringe under aseptic conditions, and the tip of the needle was sealed with a rubber stopper and sent for examination immediately. Neonatal umbilical artery blood gases were measured by a fully automated blood gas analyzer (Werfen, USA) for Pondus Hydrogenii (pH), partial

pressure of arterial oxygen (PaO_2) and partial pressure of arterial carbon dioxide (PaCO_2). The measuring period is controlled within 30 min to ensure that the samples are not exposed to air for too long or mixed with air to cause errors.

Pulmonary ultrasonography

LUS was performed in infants within 6 h after birth. In the supine, lateral or prone position, each side of lung was classified as 6 regions: anterior superior, anterior inferior, supra-axillary, sub-axillary, posterior superior and posterior inferior by connecting the parasternal, anterior axillary, posterior axillary, posterior median, and biparietal nipple lines. From top to bottom and from left to right, ultrasound was performed and registered in the 12 regions of both lungs. The scoring methodology is referenced from previous studies, with each region scoring 4 points on a scale of 0–48, with higher scores representing more severe conditions [14, 15].

RNA extraction and qRT-PCR

Venous blood was obtained in neonates within 3 h of delivery, and serum was gained by low-temperature centrifugation. Total RNA was acquired from serum by TRIzol reagent (Invitrogen, USA). RNA concentrations and OD260/280 were established by NanoDrop 2000 (Invitrogen, USA) with DEPC water (Invitrogen, USA) as a control. Extracted RNA was reverse transcribed to cDNA using PrimeScript RT Reagent Kit (TaKaRa, Japan). The qRT-PCR reaction was undertaken following the instructions of the SYBR Green I Master Mix kit (Invitrogen, USA). The relative miR-221-3p level is estimated based on U6 as an internal reference gene.

Prognostic record

The NRDS infants enrolled in the study were categorized as good and poor prognosis groups according to their recovery after 28 days of treatment. In good prognosis

group, infants had stable vital signs, significantly lower or totally resolved respiratory disturbances, and essentially normal chest radiographs. In poor prognosis group, the neonates had unstable vital signs, required mechanical ventilation support, suffered from serious complications such as patent ductus arteriosus, pulmonary hypertension, intracranial hemorrhage, or even die, or had family members who requested treatment to be abandoned.

Statistical analysis

Data were characterized using SPSS 27.0 and GraphPad Prism 9. Normally distributed data were reported as mean \pm standard deviation (SD), and independent samples t-test were used for comparisons between groups. The impact of miR-221-3p expression on prognosis to NRDS infants using Kaplan-Meier curve and COX analyses. The predictive value of miR-221-3p combined with arterial blood gas parameters and LUS score for mortality in NRDS children was assessed by plotting ROC curves. Correlation analysis was applied using Pearson analysis. $P < 0.05$ was set as a level of significance test.

Results

Clinical features of newborns

This study included 122 NRDS and 99 healthy infants, and their general information was shown in Table 1. The healthy infants included 54 males and 45 females, with a gestational age of 32.82 ± 1.64 weeks, a birth weight of 1903.43 ± 303.81 g, 59 eutocia and 40 caesarean section. There were 68 males and 54 females among the NRDS infants with gestational age of 32.13 ± 1.92 weeks, birth weight of 1841.30 ± 341.67 g, 63 eutocia and 59 caesarean section. The analysis demonstrated that NRDS did not differ markedly from healthy infants in gender, gestational age, birth weight, height, and delivery mode ($P > 0.05$). Compared with healthy infants, NRDS infants had significantly lower pH and PaO_2 , and higher PaCO_2 and LUS score ($P < 0.001$).

Table 1 General information on neonates included in the study

Parameters	Healthy (n = 99)	NRDS (n = 122)	Pvalue
Gender (male/female)	54/45	68/54	0.588
Gestational age (weeks)	32.82 ± 1.64	32.13 ± 1.92	0.068
Birth weight (g)	1903.43 ± 303.81	1841.30 ± 341.67	0.159
Birth height(cm)	45.73 ± 2.75	44.45 ± 2.94	0.065
Delivery mode (eutocia/ Cesarean section)	59/40	63/59	0.239
pH	7.37 ± 0.20	7.19 ± 0.23	< 0.001
PaO_2 (mmHg)	74.25 ± 6.15	51.19 ± 5.90	< 0.001
PaCO_2 (mmHg)	40.17 ± 2.87	49.66 ± 5.22	< 0.001
LUS score	23.95 ± 2.95	38.28 ± 3.08	< 0.001

Notes: NRDS, neonatal respiratory distress syndrome, pH, Pondus Hydrogenii; LUS, Lung ultrasound. All data were presented as mean \pm standard deviation or n

Effect of miR-221-3p on the prognosis of NRDS infants

Serum miR-221-3p levels were markedly raised in NRDS infants compared to healthy ($P < 0.001$, Fig. 1A). All neonates entered the research were categorized into high and low expression groups depending on the median miR-221-3p value, and the Kaplan-Meier curve suggested that miR-221-3p high expression group had a poor prognosis (Fig. 1B). Multivariate Cox analysis revealed miR-221-3p was markedly linked to prognosis of NRDS infants ($P = 0.015$), besides pH and LUS score were also related to the prognosis ($P = 0.049$, $P = 0.029$, Table 2).




Fig. 1 Impact of miR-221-3p on the prognosis of NRDS infants. **(A)** miR-221-3p expression in healthy and NRDS infants. **(B)** Impact of miR-221-3p differential expression on prognosis of NRDS infants. *** $P < 0.001$

Table 2 Multivariate Cox analysis of detection factors and prognosis of NRDS infants

Factors	HR	95%CI	P
miR-221-3p	4.835	1.353–17.278	0.015
pH	0.281	0.080–0.994	0.049
PaO ₂ (mmHg)	0.586	0.179–1.920	0.378
PaCO ₂ (mmHg)	1.414	0.424–4.714	0.572
LUS score	3.917	1.152–13.322	0.029

Notes: HR, Hazard ratio; 95%CI, 95% Confidence interval; pH, Pondus Hydrogenii; LUS, Lung ultrasound

Detection of miR-221-3p, pH, PaO₂, PaCO₂ and LUS score for prognosis in NRDS infants

Serum miR-221-3p levels were checked in NRDS infants in the good and poor prognosis groups, and miR-221-3p was markedly overexpressed in poor prognosis compared with the good prognosis ($P < 0.001$, Fig. 2A). Arterial blood gas parameters analysis demonstrated lower pH and PaO₂ levels in poor prognosis group, and the discrepancy was notable ($P < 0.001$, Fig. 2B and C). In contrast, PaCO₂ was considerably higher in poor prognosis group ($P < 0.001$, Fig. 2D). The lung 12-region LUS score was performed on the NRDS neonates and revealed that the total score was considerably greater in poor prognosis as compared to good prognosis ($P < 0.001$, Fig. 2E).

Predictive value of miR-221-3p combined pH, PaO₂, PaCO₂, and LUS score

ROC analysis was employed to evaluate the prognostic value of miR-221-3p combined with arterial blood gas parameters and LUS score in NRDS infants. The ROC curve result revealed that miR-221-3p predicted survival in NRDS infants with an AUC of 0.866. The AUC

in arterial blood gas parameters pH, PaO₂ and PaCO₂ to forecast survival in NRDS infants were 0.835, 0.832 and 0.839, respectively. The AUC for LUS score to predict survival in NRDS infants was 0.848. In addition, the combined analysis suggested that miR-221-3p in combination with each arterial blood gas parameter and LUS score showed a greater value in predicting survival outcomes in NRDS infants, with an AUC of 0.987 (Fig. 3; Table 3).

Correlation of miR-221-3p with pH, PaO₂, PaCO₂ and LUS score

Pearson correlation analysis was adopted to explore the relationship between miR-221-3p levels and arterial blood gas parameters and LUS score in NRDS infants. The findings revealed that miR-221-3p levels exhibited a negative link to pH and PaO₂ (Fig. 4A and B). Conversely, there was a positive effect between miR-221-3p levels and PaCO₂ and LUS score (Fig. 4C and D).

Discussion

NRDS is a condition of progressive dyspnea and respiratory failure that occurs soon after delivery, and its pathogenesis is mainly related to insufficient neonatal lung surface-active substances [16]. The disease is most severe 24 to 48 h after the birth of a neonate and has a high mortality rate [17]. The NRDS care pathway develops slowly, and those who can survive neonates for more than 3 days have increased lung maturity and may gradually recover [18]. However, many infants suffer from complications of lung infections, which re-exacerbate the condition and may lead to death in severe cases. Therefore, it is essential to develop an accurate prognosis for NRDS infants and




Fig. 2 Comparison of test indicators between the good and poor prognosis groups. (A) miR-221-3p expression in different prognosis groups. (B) pH in different prognosis groups. (C) PaO₂ in different prognosis groups. (D) PaCO₂ in different prognosis groups. (E) LUS score in different prognosis groups. *** $P < 0.001$

to provide effective treatment in a timely and targeted manner.

Research on miRNAs in disease has been a hot point of interest recently. Several studies have identified the value of miRNAs in the diagnosis and prognosis of NRDS. For example, miR-338-3p is correlated with the severity of NRDS and is a biomarker for diagnosing NRDS infants [19]. miR-375 is associated with adverse survival outcomes in NRDS [20]. miR-221-3p is engaged in multiple lung diseases and tumors modulation [21, 22]. Furthermore, in vivo study indicated that miR-221-3p is highly expressed and exerts a regulatory function of NRDS [23]. The results of this experiment revealed that miR-221-3p level in NRDS infants was greater compared to healthy infants, as well as the miR-221-3p level was notably raised of the infants of poor prognosis group, which was in line with the previous related reports [13]. Clinical detection of NRDS infants is currently done by arterial blood gas analysis and X-rays. However, NRDS has similarities with wet lungs and aspiration pneumonia and requires careful judgement by doctors from a variety of sources [24]. miR-221-3p may accurately and rapidly identify NRDS infants

at the molecular level, contributing to improved diagnostic efficiency.

Arterial blood gas analysis is a confident indicator of the presence of an imbalance in the acid-base balance of the organism, as well as hypoxia and the degree of hypoxia, and it is the most tested method for the diagnosis of NRDS [25]. Study indicates that blood gas analysis can identify neonates at high risk for NRDS early and provide better and more accurate care for them [26]. The lower pH, PaO₂ or higher PaCO₂ levels imply a greater risk of asphyxia in the infant [27]. In our research, pH, PaO₂ level were lower and PaCO₂ level was higher remarkably in poor prognosis group. This suggested that there is a correlation between lower pH, PaO₂ or higher PaCO₂ levels in arterial blood gas analysis parameters and poorer survival outcomes in NRDS infants.

With the development of ultrasound technology, LUS has been widely applied in neonatal intensive care units due to its advantages of being bedside, radiation-free, and capable of dynamic multiple assessments [28]. Recently, some domestic and international studies have found that the LUS score has a predictive value in the prognostic evaluation of NRDS infants. For example, Szymanski et




Fig. 3 ROC curve of miR-221-3p combined with arterial blood gas parameters and LUS score for forecasting survival outcomes in NRDS infants

Table 3 ROC curve analysis of miR-221-3p level combined with arterial blood gas analysis and LUS score to evaluate the prognosis of NRDS infants

Factors	AUC	95%CI	Sensitivity	Specificity	P
miR-221-3p	0.866	0.801–0.931	0.800	0.759	<0.001
pH	0.835	0.759–0.912	0.743	0.701	<0.001
PaO ₂ (mmHg)	0.832	0.758–0.906	0.800	0.736	<0.001
PaCO ₂ (mmHg)	0.839	0.767–0.912	0.800	0.736	<0.001
LUS score	0.848	0.776–0.921	0.714	0.839	<0.001
Combinations	0.987	0.963–1.000	0.943	0.977	<0.001

Notes: AUC, area under curve; 95%CI, 95% Confidence interval; pH, Pondus Hydrogenii; LUS, Lung ultrasound

al. discovered that a modified LUS score predicted ventilation requirements in NRDS infants [29]. In addition, it has been reported that higher LUS scores represent a worse prognosis for NRDS infants [30]. The LUS score of poor prognosis group was significantly lower than that of good prognosis group in the study, confirming the conjecture that LUS score is associated with prognosis in NRDS infants.

In addition, arterial blood gas parameters combined with LUS score to forecast survival outcomes of patients with lung disease have been reported [31]. However, miR-221-3p combined with arterial blood gas parameters and LUS score to predict survival outcomes in NRDS infants has rarely been reported. To examine the accuracy of miR-221-3p with arterial blood gas parameters and LUS score for forecasting survival outcomes in NRDS infants, we performed a ROC analysis. The results showed that miR-221-3p combined with arterial blood gas analysis parameters and LUS score had a high AUC compared to single indicators. This suggested that this combined analysis had greater accuracy in predicting survival outcomes in NRDS infants.

To further discuss the association of high miR-221-3p expression with survival outcomes in NRDS infants. We performed a correlation study of miR-221-3p with arterial blood gas analysis parameters and LUS score. As expected, there was a negative correlation between miR-221-3p level and pH and PaO₂, and a positive correlation with PaCO₂ and LUS score. This indicated that




Fig. 4 Correlation of miR-221-3p levels with arterial blood gas parameters and LUS score in NRDS infants. (A–C) Correlation of miR-221-3p levels with arterial blood gas parameters of pH, PaO₂ or PaCO₂. (D) Correlation of miR-221-3p levels with LUS score

miR-221-3p has a potential to predict survival outcomes in NRDS infants and may serve as a biomarker for NRDS prognosis.

We made efforts for possible bias in the study. Firstly, the research objects were allocated by randomization to ensure that the two groups were similar in general information. Secondly, we established standardized operating procedures to ensure that all operations during the study followed uniform standards and to reduce inter-operator variation. Thirdly, strict procedures for collecting, recording, and storing were established to ensure the accuracy and completeness of the data. Finally, at the data analysis stage, appropriate statistical methods were used to reduce bias.

Even though, there are still some limitations of this research. We only investigated the prognostic value of miR-221-3p in combination with arterial blood gas analysis and LUS score in NRDS, without exploring its specific mechanism in NRDS. Besides, the number of subjects included in our research was small, and their numbers

and characteristics may affect the results. Therefore, we will continue to expand the sample size and deeply investigate the mechanism of miR-221-3p in NRDS to explore its functional role.

Conclusions

In this study, we focused on discussing the ability of serum miR-221-3p combined with arterial blood gas analysis parameters and LUS score in NRDS. Taken together, upregulated miR-221-3p predicted poorer survival outcomes in NRDS infants, suggesting that miR-221-3p may be a prognostic marker for NRDS. Furthermore, miR-221-3p combined with arterial blood gas parameters and LUS score had high accuracy in predicting survival outcomes in NRDS infants and may be a useful tool for clinical NRDS prognosis.

Abbreviations

NRDS	Neonatal respiratory distress syndrome
miRNAs	MicroRNAs
SD	Standard deviation

Acknowledgements

None.

Author contributions

Yanan Hou, Zhihua Liu, Zhiqiang Liu, Meixin Liang, Tao Pan, Jinfeng Wen and Jing Mo made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data, and draft of the manuscript. Yang Zhang, Meixin Liang, Tao Pan and Jinfeng Wen revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Funding

No funding.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was endorsed by the Ethics Committee of Shengli Oilfield Central Hospital and guardians of neonates voluntarily signed an informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Ultrasonography Medicine, Qinzhou Maternal and Child Health Care Hospital, Qinzhou, Guangxi, China

²Department of Ultrasound, Seventh Medical Center of Chinese PLA General Hospital, Beijing 100700, China

³Shengli Oilfield Central Hospital, Paediatric Ward 1, No.31, Jinan Road, Dongying District, Dongying 257000, Shandong, China

⁴Outpatient Department, Shengli Oilfield Central Hospital, Dongying, Shandong, China

⁵Department of Ultrasound Medicine, Huanggang Central Hospital, No.126, Qi'an Avenue, Huanggang City 438000, Hubei Province, China

Received: 15 November 2024 / Accepted: 6 April 2025

Published online: 20 May 2025

References

- De Luca D, Tingay DG, van Kaam AH, Courtney SE, Kneyber MCJ, Tissieres P, et al. Epidemiology of neonatal acute respiratory distress syndrome: prospective, multicenter, international cohort study. *pediatric critical care medicine: a journal of the society of critical care medicine and the world federation of pediatric intensive and. Crit Care Soc.* 2022;23(7):524–34. PubMed PMID: 35543390. Epub 2022/05/12. eng.
- Hogden L, Munger K, Duffek S. Neonatal respiratory distress. *South Dakota medicine: the journal of the South Dakota. State Med Association.* 2021;74(1):28–35. PubMed PMID: 33691054. Epub 2021/03/11. eng.
- Ackermann BW, Klotz D, Hentschel R, Thome UH, van Kaam AH. High-frequency ventilation in preterm infants and neonates. *Pediatr Res.* 2023;93(7):1810–8. PubMed PMID: 35136198. Pubmed Central PMCID: PMC10313521. Epub 2022/02/10. eng.
- Srinivasan S, Aggarwal N, Makhaik S, Jhobta A, Kapila S, Bhoil R. Role of lung ultrasound in diagnosing and differentiating transient tachypnea of the newborn and respiratory distress syndrome in preterm neonates. *J Ultrasonography.* 2022;22(88):e1–5. PubMed PMID: 35449705. Pubmed Central PMCID: PMC9009341. Epub 2022/04/23. eng.
- Tandircioglu UA, Melekoglu NA. Prospective evaluation of the correlation of lung ultrasonography score and blood gas parameters in neonates with respiratory distress. *Cureus.* 2023;15(7):e41716. PubMed PMID: 37575870. Pubmed Central PMCID: PMC10414769. Epub 2023/08/14. eng.
- Chen IL, Chen HL. New developments in neonatal respiratory management. *Pediatr Neonatol.* 2022;63(4):341–7. PubMed PMID: 35382987. Epub 2022/04/07. eng.
- Dargaville PA, Herting E, Soll RF. Neonatal surfactant therapy beyond respiratory distress syndrome. *Semin Fetal Neonatal Med.* 2023;28(6):101501. PubMed PMID: 38040584. Epub 2023/12/02. eng.
- Diener C, Keller A, Meese E. Emerging concepts of MiRNA therapeutics: from cells to clinic. *Trends Genet.* 2022;38(6):613–26. PubMed PMID: 35303998. Epub 2022/03/20. eng.
- Chen X, Hu J, Pan Y, Tang Z. Novel noncoding RNAs biomarkers in acute respiratory distress syndrome. *Expert Rev Respir Med.* 2020;14(3):299–306. PubMed PMID: 31903804. Epub 2020/01/07. eng.
- Tang L, Niu S, Xu J, Lu W, Zhou L. miR-221-3p is upregulated in acute pulmonary embolism complicated with pulmonary hypertension and promotes pulmonary arterial smooth muscle cells proliferation and migration by inhibiting PTEN. *Cytotechnology.* 2024;76(4):453–63. PubMed PMID: 38933873. Pubmed Central PMCID: PMC11196540. Epub 2024/06/27. eng.
- Yin G, Zhang B, Li J. miR-221-3p promotes the cell growth of non-small cell lung cancer by targeting p27. *Mol Med Rep.* 2019;20(1):604–12. PubMed PMID: 31180541. Pubmed Central PMCID: PMC6580017. Epub 2019/06/11. eng.
- Zhou X, Wen W, Shan X, Zhu W, Xu J, Guo R, et al. A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis. *Oncotarget.* 2017;8(4):6513–25. PubMed PMID: 28036284. Pubmed Central PMCID: PMC5351649. Epub 2016/12/31. eng.
- Parzibut G, Henket M, Moermans C, Struman I, Louis E, Malaise M, et al. A blood exosomal MiRNA signature in acute respiratory distress syndrome. *Front Mol Biosci.* 2021;8:640042. PubMed PMID: 34336922. Pubmed Central PMCID: PMC8319727. Epub 2021/08/03. eng.
- Sartori S, Tombesi P. Emerging roles for transthoracic ultrasonography in pulmonary diseases. *World J Radiol.* 2010;2(6):203–14. PubMed PMID: 21160632. Pubmed Central PMCID: PMC2999323. Epub 2010/12/17. eng.
- Rouby JJ, Arbelot C, Gao Y, Zhang M, Lv J, An Y, et al. Training for lung ultrasound score measurement in critically ill patients. *Am J Respir Crit Care Med.* 2018;198(3):398–401. PubMed PMID: 29557671. Pubmed Central PMCID: PMC7205011. Epub 2018/03/21. eng.
- Bi Y, Yu W, Bian W, Jin M, He Y, Wang J, et al. Metabolic and microbial dysregulation in preterm infants with neonatal respiratory distress syndrome: an early developmental perspective. *J Proteome Res.* 2024;23(8):3460–8. PubMed PMID: 39013122. Pubmed Central PMCID: PMC11301678. Epub 2024/07/16. eng.
- Donda K, Vijayakanthi N, Dapaah-Siakwan F, Bhatt P, Rastogi D, Rastogi S. Trends in epidemiology and outcomes of respiratory distress syndrome in the United States. *Pediatr Pulmonol.* 2019;54(4):405–14. PubMed PMID: 30663263. Epub 2019/01/22. eng.
- Sweet DG, Carnielli VP, Greisen G, Hallman M, Klebermass-Schrehof K, Ozek E, et al. European consensus guidelines on the management of respiratory distress syndrome: 2022 update. *Neonatology.* 2023;120(1):3–23. PubMed PMID: 36863329. Pubmed Central PMCID: PMC10064400. Epub 2023/03/03. eng.
- Zhang C, Ji Y, Wang Q, Ruan L. MiR-338-3p is a biomarker in neonatal acute respiratory distress syndrome (ARDS) and has roles in the inflammatory response of ARDS cell models. *Acta Med Okayama.* 2022;76(6):635–43. PubMed PMID: 36549765. Epub 2022/12/23. eng.
- Deng Y, Zhang R, Jiang X. Association of umbilical cord blood miR-375 with neonatal respiratory distress syndrome and adverse neonatal outcomes in premature infants. *Acta Biochim Pol.* 2022;69(3):605–11. PubMed PMID: 35763793. Epub 2022/06/29. eng.
- Shen Y, Lu H, Song G. MiR-221-3p and miR-92a-3p enhances smoking-induced inflammation in COPD. *J Clin Lab Anal.* 2021;35(7):e23857. PubMed PMID: 34097306. Pubmed Central PMCID: PMC8274981. Epub 2021/06/08. eng.
- Shan X, Zhang L, Zhu DX, Zhou X, Zhang H, Liu QX, et al. Serum MicroRNA expression profiling revealing potential diagnostic biomarkers for lung adenocarcinoma. *Chin Med J.* 2020;133(21):2532–42. PubMed PMID: 32947363. Pubmed Central PMCID: PMC7722592. Epub 2020/09/19. eng.
- Hu L, Ye H, Liao J. LncRNA TUG1 reverses LPS-induced cell apoptosis and inflammation of macrophage via targeting MiR-221-3p/SPRED2 axis. *Biosci Biotechnol Biochem.* 2020;84(12):2458–65. PubMed PMID: 32841583. Epub 2020/08/26. eng.
- Haggag YI, Mashhour K, Ahmed K, Samir N, Radwan W. Effectiveness of lung ultrasound in comparison with chest X-Ray in diagnosis of lung

- consolidation. *Open Access Macedonian J Med Sci.* 2019;7(15):2457–61. PubMed PMID: 31666847. Pubmed Central PMCID: PMC6814487. Epub 2019/11/02. eng.
25. Yee J, Frinak S, Mohiuddin N, Uduman J. Fundamentals of arterial blood gas interpretation. *Kidney360.* 2022;3(8):1458–66. PubMed PMID: 36176645. Pubmed Central PMCID: PMC9416819. Epub 2022/10/01. eng.
26. De Bernardo G, De Santis R, Giordano M, Sordino D, Buonocore G, Perrone S. Predict respiratory distress syndrome by umbilical cord blood gas analysis in newborns with reassuring Apgar score. *Ital J Pediatr.* 2020;46(1):20. PubMed PMID: 32050997. Pubmed Central PMCID: PMC7017611. Epub 2020/02/14. eng.
27. Bass CM, Sajed DR, Adedipe AA, West TE. Pulmonary ultrasound and pulse oximetry versus chest radiography and arterial blood gas analysis for the diagnosis of acute respiratory distress syndrome: a pilot study. *Crit Care (London England).* 2015;19(1):282. PubMed PMID: 26325623. Pubmed Central PMCID: PMC4511255. Epub 2015/09/02. eng.
28. Raimondi F, Migliaro F, Corsini I, Meneghin F, Dolce P, Pierri L et al. Lung ultrasound score progress in neonatal respiratory distress syndrome. *Pediatrics.* 2021;147(4). PubMed PMID: 33688032. Epub 2021/03/11. eng.
29. Szymański P, Kruczek P, Hożejowski R, Wais P. Modified lung ultrasound score predicts ventilation requirements in neonatal respiratory distress syndrome. *BMC Pediatr.* 2021;21(1):17. PubMed PMID: 33407270. Pubmed Central PMCID: PMC7785923. Epub 2021/01/08. eng.
30. Szymański P, Puskarz-Gąsowska J, Hożejowski R, Stefańska M, Błaż W, Sadowska-Krawczyńska I, et al. Prognostic relevance of the lung ultrasound score: a multioutcome study in infants with respiratory distress syndrome. *Am J Perinatol.* 2024;41(S 01):e2862–9. PubMed PMID: 37848043. Pubmed Central PMCID: PMC11150063 for lecturing and participation on advisory boards. R.H. is employed by Chiesi Poland, the sponsor of the study. The remaining authors report no conflict of interest. Epub 2023/10/18. eng.
31. Yin K, Xu Q, Wang J, Ouyang S, Zhu Q, Lai J. The predictive value of lung ultrasound combined with central venous oxygen saturation variations in the outcome of ventilator weaning in patients after thoracic surgery. *Am J Translational Res.* 2022;14(12):8621–31. PubMed PMID: 36628206. Pubmed Central PMCID: PMC9827289. Epub 2023/01/12. eng.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.